In breast, colorectal and pancreatic tumors, CAFs increase the resistance of cells to chemotherapeutic agents like gemcitabine and doxorubicin and to combination chemotherapy like doxorubicin, 5-fluorouracil and cisplatin through the production of IL-6, IL-17A, PDGF and insulin like growth factor (IGF) that activate the NF-κB and ERK pathways in tumor cells, promoting the stabilization of anti-apoptotic proteins and the proliferation of cancer stem cells [91,92,93,94,95]. Here, NFKB1 is linked to neoplasm.